MYX mayne pharma group limited

Ann: FDA approval of HALOETTE, a generic version of NUVARING, page-23

  1. 1,467 Posts.
    lightbulb Created with Sketch. 289
    " another product we could actually lose money on " . Until company reports net profit think we're unlikely to see decent share improvement . Company obviously makes good money but at the end of the day its all about how much what we're left with , net profit . With our track record of net loses and buying costly products/ leases which have yet to prove their worth not hard to see why share value pretty much going nowhere but side way's . Until there's real evidence our costly products/ leases likely to pay off even if they do within a reasonable time frame , company needs to keep generating enough income to be able to afford carrying these products that hopefully makes money for us eventually . Hard to see net profit anytime soon ( hope I'm wrong) just hoping company reports impressive turnover and an acceptable level of debt + net profit expected not too far away .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$4.91
Change
-0.120(2.39%)
Mkt cap ! $399.7M
Open High Low Value Volume
$5.03 $5.03 $4.86 $1.624M 330.5K

Buyers (Bids)

No. Vol. Price($)
9 2223 $4.91
 

Sellers (Offers)

Price($) Vol. No.
$4.93 5737 18
View Market Depth
Last trade - 15.55pm 23/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.